November 27, 2017
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Aerie posts $32.4 million quarterly loss
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Aerie Pharmaceuticals reported a net loss of $32.4 million, or $0.89 per share, in 2017’s third quarter compared with a net loss of $23.8 million, or $0.81 per share, in the same quarter last year, according to a press release.
Total operating expenses were $32.2 million, which includes $12.4 million in research and development costs and $19.8 million in selling, general and administrative costs, whereas 2016’s third quarter operating expenses totaled $23.8 million. The increase was attributed to more activities to support the growth of operations and preparation for commercialization efforts of Rhopressa (netarsudil ophthalmic solution 0.02%), the release said.
Cash, cash equivalents and investments totaled $282.2 million as of Sept. 30.